BMC Neuroscience 2012-01-01

Differential effects of AdOx on gene expression in P19 embryonal carcinoma cells.

Li Yan, Hai-Yong Zhao, Ye Zhang, Yu-Fei Shen

Index: BMC Neurosci. 13 , 6, (2012)

Full Text: HTML

Abstract

Pluripotent cells maintain a unique gene expression pattern and specific chromatin signature. In this study, we explored the effect of the methyltransferase inhibitor adenosine dialdehyde (AdOx) on pluripotency maintenance and gene expression in P19 embryonal carcinoma cells.After AdOx treatment, the pluripotency-related gene network became disordered, and the early developmental genes were released from the repression. Remarkably, AdOx caused contrasting effects on the expression of two key pluripotency genes, nanog and oct3/4, with the reduction of the repressive histone marks H3K27me3, H3K9me3 and H3K9me2 only in the nanog gene.Key pluripotency genes were controlled by different mechanisms, including the differential enrichment of repressive histone methylation marks. These data provided novel clues regarding the critical role of histone methylation in the maintenance of pluripotency and the determination of cell fate in P19 pluripotent cells.

Related Compounds

  • Adenosine dialdehy...

Related Articles:

Elasticity assessment of electrospun nanofibrous vascular grafts: a comparison with femoral ovine arteries.

2014-12-01

[Mater. Sci. Eng. C. Mater. Biol. Appl. 45 , 446-54, (2014)]

Efflux of glutathione and glutathione complexes from human erythrocytes in response to vanadate.

2013-01-01

[Blood Cells Mol. Dis. 50(1) , 1-7, (2013)]

Involvement of Src and the actin cytoskeleton in the antitumorigenic action of adenosine dialdehyde.

2013-04-15

[Biochem. Pharmacol. 85(8) , 1042-56, (2013)]

Increased plasma S-adenosylhomocysteine-accelerated atherosclerosis is associated with epigenetic regulation of endoplasmic reticulum stress in apoE-/- mice.

2015-01-01

[Arterioscler. Thromb. Vasc. Biol. 35(1) , 60-70, (2015)]

Adenosine dialdehyde suppresses MMP-9-mediated invasion of cancer cells by blocking the Ras/Raf-1/ERK/AP-1 signaling pathway.

2013-11-01

[Biochem. Pharmacol. 86(9) , 1285-300, (2013)]

More Articles...